Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Exagen (XGN) Research & Development (2018 - 2025)

Historic Research & Development for Exagen (XGN) over the last 8 years, with Q3 2025 value amounting to $1.7 million.

  • Exagen's Research & Development rose 1681.3% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.2 million, marking a year-over-year increase of 2832.12%. This contributed to the annual value of $5.4 million for FY2024, which is 1048.3% up from last year.
  • According to the latest figures from Q3 2025, Exagen's Research & Development is $1.7 million, which was up 1681.3% from $1.5 million recorded in Q2 2025.
  • In the past 5 years, Exagen's Research & Development ranged from a high of $2.7 million in Q4 2022 and a low of $1.1 million during Q1 2024
  • For the 5-year period, Exagen's Research & Development averaged around $1.7 million, with its median value being $1.5 million (2025).
  • Its Research & Development has fluctuated over the past 5 years, first soared by 15193.08% in 2021, then crashed by 6016.29% in 2023.
  • Over the past 5 years, Exagen's Research & Development (Quarter) stood at $2.2 million in 2021, then grew by 22.66% to $2.7 million in 2022, then crashed by 60.16% to $1.1 million in 2023, then skyrocketed by 53.9% to $1.7 million in 2024, then rose by 4.47% to $1.7 million in 2025.
  • Its Research & Development was $1.7 million in Q3 2025, compared to $1.5 million in Q2 2025 and $1.3 million in Q1 2025.